Clinical trial
Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With…
NCT00237484 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00237484 |
|---|---|
| Title | Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED) |
| Official title | Effect of Infliximab in Hepatitis-C Genotype 1 Naïve Patients With High TNF-alpha on the Efficacy of Pegylated Interferon Alfa-2b/Ribavirin Therapy |
| Acronym | Pegade |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin, Combination of (a) pegylated interferon alfa-2b and (b) ribavirin |
| Enrollment | 89 |
| Start date | Jul 18, 2005 |
| Primary completion | Jun 30, 2011 |
| Completion | Jun 30, 2011 |
| First posted | Oct 12, 2005 |
| Last update posted | Aug 26, 2020 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: